US 11,987,560 B2
Inhibitors of lysine specific demethylase-1
Young K. Chen, San Marcos, CA (US); Toufike Kanouni, Rancho Santa Fe, CA (US); Stephen W. Kaldor, San Diego, CA (US); Jeffrey Alan Stafford, San Diego, CA (US); and James Marvin Veal, Apex, NC (US)
Assigned to Celgene Quanticel Research, Inc., San Diego, CA (US)
Filed by CELGENE QUANTICEL RESEARCH, INC., San Diego, CA (US)
Filed on Jun. 23, 2021, as Appl. No. 17/356,389.
Application 17/356,389 is a continuation of application No. 16/841,595, filed on Apr. 6, 2020, granted, now 11,084,793.
Application 16/841,595 is a continuation of application No. 16/007,937, filed on Jun. 13, 2018, granted, now 10,654,810.
Application 16/007,937 is a continuation of application No. 15/687,251, filed on Aug. 25, 2017, granted, now 10,023,543.
Application 15/687,251 is a continuation of application No. 15/401,894, filed on Jan. 9, 2017, granted, now 9,776,974.
Application 15/401,894 is a continuation of application No. 14/988,022, filed on Jan. 5, 2016, granted, now 9,573,930.
Application 14/988,022 is a continuation of application No. 14/701,304, filed on Apr. 30, 2015, granted, now 9,255,097.
Claims priority of provisional application 61/987,354, filed on May 1, 2014.
Prior Publication US 2022/0153706 A1, May 19, 2022
This patent is subject to a terminal disclaimer.
Int. Cl. C07D 239/47 (2006.01); A61K 31/4545 (2006.01); A61K 31/513 (2006.01); A61K 31/5377 (2006.01); A61K 31/551 (2006.01); C07B 59/00 (2006.01); C07D 239/36 (2006.01); C07D 401/04 (2006.01); C07D 401/12 (2006.01); C07D 401/14 (2006.01); C07D 403/04 (2006.01); C07D 403/12 (2006.01); C07D 403/14 (2006.01); C07D 405/14 (2006.01); C07D 471/10 (2006.01)
CPC C07D 239/47 (2013.01) [A61K 31/4545 (2013.01); A61K 31/513 (2013.01); A61K 31/5377 (2013.01); A61K 31/551 (2013.01); C07B 59/002 (2013.01); C07D 239/36 (2013.01); C07D 401/04 (2013.01); C07D 401/12 (2013.01); C07D 401/14 (2013.01); C07D 403/04 (2013.01); C07D 403/12 (2013.01); C07D 403/14 (2013.01); C07D 405/14 (2013.01); C07D 471/10 (2013.01); C07B 2200/05 (2013.01)] 4 Claims
 
1. A method for treating cancer selected from the group consisting of acute myeloid leukemia (AML), breast cancer, and prostate cancer in a subject in need thereof comprising administering to the subject a therapeutically effective dose of a compound of Formula (I), or a pharmaceutically acceptable salt thereof:

OG Complex Work Unit Chemistry
wherein:
W is N, C—H, or C—F;
Y is hydrogen, optionally substituted alkyl, optionally substituted cycloalkyl, or optionally substituted cycloalkylalkyl; and
(i) X is hydrogen, halogen, —CN, optionally substituted alkyl, optionally substituted alkynyl, optionally substituted carbocyclylalkynyl, or optionally substituted heteroaryl; and
Z is an optionally substituted group chosen from alkyl, carbocyclyl, C-attached heterocyclyl, N-attached heterocyclyl, heterocyclylalkyl, heterocyclylalkenyl, —O-heterocyclyl, —N(R)-heterocyclyl, —O-heterocyclylalkyl, —N(R)-heterocyclylalkyl, —N(R)(C1-C4alkylene)-NR2, or —O(C1-C4alkylene)-NR2; wherein R is hydrogen or C1-C4alkyl; or
(ii) X is optionally substituted aryl; and
Z is an optionally substituted group chosen from C-attached heterocyclyl, heterocyclylalkyl, heterocyclylalkenyl, —O-heterocyclyl, —N(R)-heterocyclyl, —O—heterocyclylalkyl, —N(R)-heterocyclylalkyl, —N(R)(C1-C4alkylene)-NR2, or —O(C1-C4alkylene)-NR2; wherein R is hydrogen or C1-C4alkyl.